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Abstract
Purpose: This study has focused on investigating the relationship between the exponential apparent diffusion coef-
ficient (exp-ADC), selective apparent diffusion coefficient (sel-ADC) values, the ADC ratio (ADCr), and prostate 
cancer aggressiveness with transrectal ultrasound-guided prostate biopsy in patients with prostate cancer.
Material and methods: All patients underwent a multiparametric magnetic resonance imaging (mpMRI) including 
tri-planar T2-weighted (T2W), dynamic contrast-enhanced (DCE), diffusion-weighted sequences using a 3.0-Tesla 
MR scanner (Skyra, Siemens Medical Systems, Germany) with a dedicated 18-channel body coil and a spine coil 
underneath the pelvis, with the patient in the supine position. Exp-ADC, sel-ADC, and ADCr of defined lesions 
were evaluated using region-of-interest-based measurements. Exp-ADC, sel-ADC, and ADCr were correlated with 
the Gleason score obtained through transrectal ultrasound-guided biopsy.
Results: Patients were divided into 2 groups. Group I is Gleason score ≥ 3 + 4, group II is Gleason score = 6. Sel-ADC and 
exp-ADC were statistically significant between 2 groups (0.014 and 0.012, respectively). However, the ADCr difference 
between nonclinical significant prostate cancer from clinically significant prostate cancer was not significant (p = 0.09).
Conclusions: This study is the first to evaluate exp-ADC and sel-ADC values of prostate carcinoma with ADCr. One 
limitation of this study might be the limited number of patients. Exp-ADC and sel-ADC values in prostate MRI 
imaging improved the specificity, accuracy, and area under the curve (AUC) for detecting clinically relevant prostate 
carcinoma. Adding exp-ADC and sel-ADC values to ADCr can be used to increase the diagnostic accuracy of DWI.
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Introduction
Prostate cancer (PCa) is the most common noncutaneous 
malignancy among Western men and the leading cause 
of cancer mortality, preceded only by lung cancer in the 
United States, with an annual incidence of 161,360 cases 
resulting in 26,730 deaths in 2018 [1]. PCa is most often 
diagnosed on systematic transrectal ultrasound (TRUS)-
guided prostate biopsy. TRUS-guided prostate biopsy is 
considered the gold standard for diagnosis of PCa, which 
should include 12 cores, thereby leading to a detection 
rate ranging between 24% and 44% according to the cur-
rent European Association of Urology (EAU) guidelines.
It is crucial to diagnose tumour aggressiveness or, in 
other words, to correctly differentiate nonclinical signifi-
cant prostate cancer (ncsPCa) from clinically significant 
prostate cancer (csPCa), to apply the appropriate treat-
ment modalities and reduce overtreatment or ineffective 
treatment results [2,3]. CsPCa is defined as GS ≥ 3 + 4 = 7, 
tumour measuring ≥ 0.5 cm3, or showing features of 
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extra prostatic extension [4]. PCa is primarily based 
on prostate-specific antigen (PSA) screening and 
TRUS-guided prostate biopsy. However, prostatitis can 
also cause elevated PSA, and normal PSA does not ex-
clude a tumour [5,6].
Multiparametric magnetic resonance imaging (MpMRI) 
has assumed a primary role in the diagnosis of PCa; it 
is non-invasive and the gold standard diagnostic imag-
ing modality for PCa, which is a combination of standard 
anatomical T1- and T2-weighted imaging with functional 
imaging techniques (diffusion-weighted imaging [DWI] 
and dynamic contrast-enhanced MRI). DWI measures 
the Brownian motion of water molecules in vivo on un-
enhanced MRI sequences and provides information about 
tissue cellularity and membrane integrity. It has shown 
potential to increase the accuracy of tumour detection, lo-
calization, and characterization of prostate cancer [7-10]. 
We can measure the water molecules’ mobility (Brownian 
motion) in vivo on unenhanced MRI sequences and also 
provide apparent diffusion coefficient (ADC) map-derived 
DWI sequences, which are used to inversely correlate with 
cellularity in different tumour types, provides quantita-
tive information about tumour aggressiveness, and has 
shown an overall high correlation with Gleason score (GS) 
[11,12]. However, in some reported studies, the ranges of 
ADC values have again demonstrated significant overlaps 
within the same GS groups [13,14].
To avoid these inconsistencies and standardize the 
quantitative metrics, the ADC selective (sel-ADC), ADC 
exponential (exp-ADC), and ADC ratio (ADCr) (the 
quan titative parameter ratio between the tumour and non- 
tumoural prostatic tissue) were also evaluated in this 
study. Several earlier studies demonstrated that the ADCr 
had better correlation with GS than the mean ADC value 
[15,16] as well as a favourable impact on diagnostic perfor-
mance [17].
This study aims to investigate the relationship between 
ADC parameters and Gleason score with the aid of histo-
pathological findings by TRUS-guided prostate biopsy in 
patients with prostate cancer.
Material and methods
Study population
This retrospective study was approved by the responsible 
ethics committee. We performed a search using our in-
stitutional Picture Archiving and Data Reporting System 
(PACS; Centricity, General Electric CA, U.S.) to identify 
all patients who underwent multiparametric prostate MRI 
and TRUS-guided biopsy of the prostate between July 
2016 and March 2019. Forty-four consecutive patients 
were retrospectively included in the study with the fol-
lowing including criteria: a) 3-Tesla MR platform with 
an 18-channel phased array surface coil and a spine coil 
underneath the pelvis; b) at least 1 suspicious lesion with 
a large axial diameter of 5 mm in the peripheral zone and 
a PIRADS-v2 score > 3 – each identified lesion is scored 
according to the PIRADS v2 classification system from 
ESUR; c) each patient was diagnosed as prostatic adeno-
carcinoma histopathologically with TRUS biopsy using 
a Loqic E9 (General Electric Healthcare) PSA – PSA den-
sity levels and prostate volumes were recorded – TRUS-
guided prostate biopsy was performed involving 14 cores 
after the magnetic resonance imaging (MRI) examina-
tions.
Magnetic resonance imaging protocols and imaging 
analysis
Magnetic resonance imaging acquisition
All patients underwent a multiparametric prostate MRI in-
cluding tri-planar T2-weighted (T2W), dynamic contrast-
enhanced (DCE), diffusion-weighted imaging sequences 
using a 3.0-Tesla MR scanner (Skyra, Siemens Medical 
Systems, Germany) with a dedicated 18-channel body coil 
and a spine coil underneath the pelvis, with the patient in 
the supine position. Routinely, just before the beginning of 
the examination, 20 mg butylscopolamine bromide (Bus-
copan, Boehringer Ingelheim, Germany) was injected (i.m.) 
to reduce bowel movements. 135 ml sodium di-hydrogen 
phosphate + di-sodium hydrogen phosphate (B.T. enema) 
was administrated to the patient to reduce motion artifacts 
due to bowel peristalsis. We imaged the entire prostate and 
oriented axial images to be perpendicular to the rectal wall 
guided by sagittal images.
Prostate MRI was done using the following protocol 
– axial T2-weighted (T2W) sequence (TR/TE 3200/96 
ms; slice thickness 3.5 mm with 0.5 mm interslice gap; 
field of view [FOV] 200 × 200 mm; matrix size 448 × 336; 
average 2) sagittal T2W volumetric space sequence (TR/
TE 1500/139 ms; slice thickness 0.9 mm without any in-
terslice gap; FOV 220 × 220 mm; matrix size 256 × 205; 
average 1.4); a coronal T2W sequence (TR/TE 4870/117 
ms; slice thickness 3 mm with 0.6 mm interslice gap; FOV 
240 × 240; matrix size 314 × 448; average 1) echo planar 
imaging (EPI)-based DWI sequence in axial planes at 
b values of 50, 400, 1000, 1400 s/mm2 (TR/TE 4100/61 ms; 
slice thickness 3.5 mm; FOV 200 × 200, and matrix size 
114 × 114); an axial multiphase 3-dimensional (3D) 
T1W dynamic gradient-echo sequence obtained after 
10 ml intravenous bolus injection of 0.1 mmol gadobutrol 
(Gadovist; Bayer Laboratories, Berlin, Germany) per ki-
logram of body weight followed by a 20 ml saline flush at 
a rate of 2.0 ml/s. Approximately 32 series were obtained, 
which lasted for a total of 8 minutes with flip angle 15°; 
slice thickness 3.5 mm with 0.6 mm interslice gap; FOV 
220 × 220; matrix 80 × 192, average 1 mm.
Pelvic postcontrast T1 axial fat-saturated Turbo Spin 
Echo (TSE; TR/TE 515/20; slice thickness 5 mm with 
1 mm interslice gap, FOV 350 × 350, matrix 320 × 240; 
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average 1 mm and axial Short Tau Inversion Recovery 
(STIR); TR/TE 4550/91; slice thickness 5 mm with 1 mm 
interslice gap, FOV 350 × 350, matrix 384 × 269; average 
1 mm) sequences were obtained.
The ADC maps were constructed from DWI images 
by using the mono-exponential model. Calculated and 
acquired high b-value DWI images were compared for 
lesion visibility and image quality by a radiologist with 
5 years’ experience in prostate with knowledge of the 
pathology data.  Signal intensities on the high b-value 
(1400 s/mm2) images of the peripheral zone, and the de-
fined lesions were visualized. The exponential exp-ADC, 
sel-ADC, and ADCr of defined lesions were evaluated us-
ing region of interest-based measurements. The exp-ADC 
value calculated for the suspected lesion by drawing a re-
gion of interest (ROI) around the suspicious lesion us-
ing a ROI covering the whole of the lesion. Sel-ADC was 
measured, using a region of interest (ROI) of 5-10 mm2 
at the area of lowest ADC value within the lesion. ADCr 
was calculated as ADC tumour/ADC mirror normal-ap-
pearing prostate parenchyma. Exp-ADC, sel-ADC, and 
ADCr were correlated with the Gleason score obtained 
via transrectal ultrasound-guided biopsy. The cases were 
classified into 2 groups, according to their Gleason score, 
as group I with Gleason score 6, and Gleason score 7-10 
stratified as Group II.
Each biopsy was performed in a left lateral decubitus 
position. We used endocavitary 4 to 10 MHz broadband 
curved array endfire transducer with Logiq E9 (General 
Electric Healthcare) and an 18-20 gauge cutting core bi-
opsy needle. Patients first underwent systematic 14-core 
biopsies (6 from each lobe and 1 more from each transi-
tional zone), followed by targeted biopsies generally con-
sisting of 2 or 3 cores from each target.
Histopathology analysis
A genitourinary pathologist with 20 years’ experience 
reviewed and described all biopsy cores. The specimens 
were stained with haematoxylin-eosin under a light mi-
croscope (Olympus BX51, Olympus Corporation, Tokyo 
163-0914, Japan). The tumours from all patients were clas-
sified into Gleason score. 
The biopsy data included the number of positive biopsy 
cores, Gleason score, and the maximal percentage of in-
volvement for each positive biopsy core.
Statistical analysis
All statistical analyses were carried out using Windows for 
SPSS v. 22 (IBM Corporation, New York, USA). The mean 
sel-ADC and exp-ADC and ADCr values were compared 
between 2 groups. PSA and PSA density were assessed 
if there was a statistically significant difference between 
2 groups. PSA and PSA density were assessed if there was 
a statistically significant difference between 2 groups.
Continuous variables were assessed using the Shapiro-
Wilks test for normality of data and presented as mean 
± SD or median (range). The Mann-Whitney U test or Stu-
dent’s t-test were performed to compare non-parametric 
and parametric variables. Also, receiver operating char-
acteristic (ROC) curve analysis and areas under the curve 
(AUCs) were performed for each statistically significant 
parameter to establish an optimal cut-off value and to as-
sess the discrimination ability of each parameter for non-
significant Pca versus clinically significant PCa. The best 
cut-off point was determined by using the Youden S index. 
Also, parameters were compared between the study and 
control groups with independent samples t-test. 
Spearman’s rank correlation analysis was used to show 
the correlations of aggressiveness of prostate Ca with 
sel-ADC, exp-ADC, and ADCr values. P < 0.05 was con-
sidered statistically significant. 
Results
A total of 69 patients were enrolled in this study. Forty- 
four patients with Pca formed the study group, and 25 pa-
tients were observed to have no Pca with mpMRI. The me-
dian patient age in the study group was 61.02 ± 6.08 years 
(range, 50 to 84 years). The mean PSA was 6.34 ± 2.56 ng/
ml, and the median PSA Density was 0.16 ± 0.09. With re-
spect to histopathological analysis, we identified 17 patients 
with a GS of 6; 20 patients with a GS of 7; 2 patients with 
a GS of 8; 4 patients with a GS of 9; and 1 patient with a GS 
of 10. Eleven patients had multi focal Pca in the study group. 
The GS of multifocal Pca group was 7 in 6 patients, and all 
of the patients with GS 8, 9, and 10 had multifocal Pca. 
There was a nonsignificant correlation between PSA 
level and Gleason score (p = 0.6), but there was a signifi-
cant difference between the 2 groups in terms of PSA den-
sity (p = 0.015). The ADCr was not significant between 
2 groups, while sel-ADC and exp-ADC were statistically 
significant (p = 0.09, 0.014, 0.012, respectively) (Table 1). 
The mean exp-ADC and sel-ADC values were sig-
nificantly lower in high-grade Pca than in low-grade Pca 
(p = 0.012 and 0.014, respectively). However, the mean 
ADCr value difference between nsPca and sPca was not 
significant (p = 0.09).
Table 1. Relationship between parameters and Gleason scores
Parameter Mean SD Gleason 
score = 6
Gleason score  
≥ 3 + 4 
Age 61.02 ± 6.08 62.04 60.8 0.27
PSA 6.34 ± 2.56 4.34 7.02 0.6
PSA density 0.16 ± 0.09 0.14 0.18 0.015
Exp-ADC 772.93 ± 180.11 862.44 723.55 0.014
Sel-ADC 639.64 ± 162.94 718.63 596.07 0.012
ADCr 6.34 ± 2.56 0.64 0.54 0.09
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ROC analysis was performed to obtain an optimal cut-
off value for the sel-ADC and exp-ADC value to differen-
tiate 2 groups (area under the curve = 0.719 and 0.726, re-
spectively) (Figure 1). A sel-ADC value ≤ 684 mm2/s has 
a sensitivity, specificity, positive predictive value, negative 
predictive value, of 79.31, 62.50, 79.3, and 62.5 respec-
tively, to differentiate nsPca from sPca. An exp-ADC value 
≤ 731 mm2/s has a sensitivity, specificity, positive predic-
tive value, and negative predictive value of 55.17, 87.50, 
69, and 56.3, respectively, to differentiate nsPca from sPca. 
The AUC of exp-ADC was 0.726, AUCs of sel-ADC 
were 0.719 and ADCr was 0.702, respectively (Figure 1). 
The exp-ADC values were thus strongly associated with 
higher tumour aggressiveness in this study. 
The sel-ADC value was 0.718 ± 0.161 × 10−3 mm2/s 
for Group I; 0.596 ± 0.148 × 10−3 mm2/s for Group II; 
the exp-ADC was 0.862 ± 0.188 × 10−3 mm2/s for Group I; 
and 0.723 ± 0.157 × 10−3 mm2/s for Group II, the ADCr 
was 0.64 ± 0.2 for Group I and 0.54 ± 0.15 for Group II. 
Figure 1. Area under the curve (AUC) of exp-ADC was 0.726, AUCs of sel-ADC 
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Figure 2. A 67-year-old patient with Gleason Score 3 + 4 prostate adeno-
carcinoma in the left peripheral zone, exp-ADC value is measured 
Figure 3. A 67-year-old patient with Gleason Score 3 + 4 prostate adeno-
carcinoma in the left peripheral zone, sel-ADC value is measured Figure 4. T2-weighted axial image of the same patient 
Representative cases with a GS of 3 + 4 and 4 + 4 prostate 
cancers in the right and left peripheral zones are shown 
in Figures 2-4 and Figures 5-8, respectively. The differ-
ences between the ADC values obtained for 2 groups were 
analysed in pairs, and there were significant differences 
between GS 6 groups with the exception of GS ≥ 3 + 4. 
Furthermore, the sel-ADC, exp-ADC, and ADCr values 
of tumours with GS ≥ 3 + 4 were significantly lower than 
that of tumours with GS = 6 (p < 0.001) (Table 1).
The relation between age, PSA, PSA density, exp-ADC, 
sel-ADC, prostate MR volume, and prostate adenocarci-
noma is shown in Table 2. ADCr could not be studied in 
the control group because there was no tumoural prostatic 
tissue in the control group. 
The age, PSA, PSA density, and prostate MR volume 
were at statistically significantly higher levels in patients 
with Pca than in the patients without pCa (p < 0.01). Exp-
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ADC and sel-ADC values were at statistically significantly 
lower levels in patients with Pca than in the cases without 
Pca (p < 0.01).
Discussion 
MRI can delineate the structure of prostate and anatomi-
cal details of the prostatic tissue. DWI, a major component 
Figure 5. A 62-year-old patient with Gleason score 4 + 4 in the right peri-
pheral zone on diffusion-weighted imaging, sel-ADC value is measured 
Figure 6. Exp-ADC value of a patient with right peripheral Gleason score 
4 + 4 prostate adenocarcinoma
Figure 7. T2-weighted image of a patient with right peripheral Gleason 
score 4 + 4 prostate adenocarcinoma 
Figure 8. Computed b value of this patient 






Age 61.02 ± 6.08 53.84 ± 12.01 0.001*a
PSA 6.34 ± 2.56 0.96 ± 0.58 0.001*a
PSA density 0.16 ± 0.09 0.02 ± 0.01 0.001*a
Ext-ADC 772.93 ± 180.11 1570.80 ± 245.29 0.001*a
Sel-ADC 639.64 ± 162.94 1540.08 ± 234.56 0.001*a
Prostate MR volume 46.46 ± 19.94 38.36 ± 19.34 0.001*a
aIndependent samples t-test, *p < 0.01
of mpMRI, has been the main sequence for detecting and 
staging prostate cancer in PZ, and it additionally provides 
information about tumour cellularity. In particular, DWI 
and ADC values are regarded as reliable non-invasive tools 
for assessing tumour aggressiveness in prostate cancer [18]. 
MRI can be a guide for prostate biopsies or demonstrates 
the anatomic location of the tumour and is a follow-up 
method for active surveillance of patients. Many stud-
ies have been performed on the discrimination between 
normal and malignant prostate tissue using the DWI tech-
nique. Because absolute ADC values depend on the selected 
b-value, the most accurate method of measuring the ADC 
value is still being discussed. Cellularity, tumour type, or 
nuclear grade can affect the ADC values of tumoural tissue. 
Therefore, different options are under investigation be-
yond ADC tumour mean value, such as the sel-ADC value, 
exp-ADC, and ADCr (expressed as the ratio between tu-
mour and non-tumour ADC values) in prostate cancer ag-
gressiveness. 
Hambrock et al. [19] showed that a significant inverse 
correlation between ADC values and Gleason score was 
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well-illustrated. Some studies have reported that ADC 
values have demonstrated significant overlaps within the 
same GS groups [10,11]. MRI acquisition parameters, 
selected b values, patient properties, and prostate gland 
structure cause differences in the obtained ADC values. 
To eliminate the effect of these parameters, this study as-
sessed the role of sel-ADC, exp-ADC, and the ADCr in 
distinguishing Gleason score 6 and Gleason Score ≥ 3 + 4. 
Our study demonstrated that exp-ADC values had high-
est specificity with 87.5% inversely correlated with GS in 
prostate cancer, and that it was feasible to discriminate be-
tween pathologic GS 6 diseases according to ADC values. 
In our study there were significant differences in sel-
ADC and exp-ADC when comparing 2 groups.
Wu et al. [20] showed that higher ADC values (0.830 
× 10-3 mm2/s) were significantly associated with low-risk 
prostate cancer (GS 6 disease).
In our study, the cut-off values for sel-ADC and exp-
ADC were 0.684 × 10-3 mm2/s and 0.731 × 10-3 mm2/s, 
respectively, for differentiating low-risk prostate cancer 
from high-risk prostate cancer. 
The decrease in ADC in high GS disease can be ex-
plained by the high tumour cellularity representing tu-
mour aggressiveness. 
Many authors affirm that the ADC ratio seems to be 
a more useful and reproducible method because it is in-
dependent of the diffusion parameters as selected b values 
and vector strength [21-24]. Nevertheless, a number of 
factors still limit ADCr’s efficacy. In our opinion, pros-
tate tissue without tumour involvement used to measure 
ADCr appears norma, but it contains benign conditions 
like prostatitis, hyperplasia, or fibrosis. 
When all these factors are taken into consideration, in 
our opinion sel-ADC and exp-ADC measurements are safe 
methods for prostate cancer aggressiveness assessment.
One limitation of this study might be the limited num-
ber of patients. Secondly, we compared our MRI param-
eters with GS.  Sometimes GS on a biopsy does not reflect 
the cancer’s true grade. Additionally, recent modifications 
have improved the Gleason grading system, but it is still 
much more complex and can be confusing for patients 
and clinicians. For example, Gleason score 7 includes both 
Gleason score 3 + 4 and 4 + 3. Many recent studies have 
shown that Gleason score 4 + 3 = 7 demonstrates worse 
pathological stage than 3 + 4 = 7, although many clini-
cians consider Gleason score 7 on biopsy to be intermedi-
ate risk [25-27].
Conclusions
Sel-ADC and exp-ADC are more useful diffusion param-
eters than ADCr for proving prostate cancer aggressive-
ness. Exp-ADC and sel-ADC measurements in diffusion 
imaging improved specificity, accuracy, and AUC for de-
tecting clinically relevant prostate carcinoma.
Our study results show that they are promising pa-
rameters to identify clinically significant prostate adeno-
carcinoma.
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